The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review

Página do item simplificado
dc.creatorJohannes Bitzer
dc.creatorThomas Römer
dc.creatorAgnaldo Lopes da Silva Filho
dc.date.accessioned2023-04-05T23:59:36Z
dc.date.accessioned2025-09-09T00:34:28Z
dc.date.available2023-04-05T23:59:36Z
dc.date.issued2017-04-27
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1080/13625187.2017.1317339
dc.identifier.issn1473-0782
dc.identifier.urihttps://hdl.handle.net/1843/51673
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofThe European Journal of Contraception & Reproductive Health Care
dc.rightsAcesso Aberto
dc.subjectHiperandrogenismo
dc.subjectAcetato de ciproterona
dc.subjectEtinilestradiol
dc.subjectHirsutismo
dc.subjectAcne vulgar
dc.subjectDermatite seborreica
dc.subjectAlopecia
dc.subjectSíndrome do ovário policístico
dc.subject.otherHyperandrogenism
dc.subject.otherCyproterone acetate
dc.subject.otherEthinylestradiol
dc.subject.otherHirsutism
dc.subject.otherAcne
dc.subject.otherSeborrhea
dc.subject.otherAlopecia
dc.subject.otherPolycystic ovary syndrome
dc.titleThe use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review
dc.typeArtigo de periódico
local.citation.epage182
local.citation.issue3
local.citation.spage172
local.citation.volume22
local.description.resumoIntroduction: Hyperandrogenism affects approximately 10–20% of women of reproductive age. Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment. Women with abnormalities in androgen metabolism may have accompanying anovulation and/or polycystic ovary syndrome (PCOS), both of which have reproductive and metabolic implications if left untreated. Cyproterone acetate (CPA), combined with ethinylestradiol (EE), is indicated for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age. Objective: To review the data on the efficacy and safety of CPA 2 mg/EE 35 lg for the treatment of hyperandrogenic skin symptoms in women. Methods: A non-systematic narrative review based on a literature search of the PubMed database. Results: Seventy eight studies were identified. The majority of sufficiently powered studies show a high efficacy of CPA 2mg/EE 35 lg in the treatment of severe acne and hirsutism. Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated. Additional benefits include cycle control and, in some women, improvement in mood and perception of body image. Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine’s Agency’s (EMA). Conclusions: This review provides a comprehensive overview about the efficacy of CPA 2mg/EE 35 lg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.
local.identifier.orcidhttps://orcid.org/0000-0002-8486-7861
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE GINECOLOGIA OBSTETRÍCIA
local.publisher.initialsUFMG
local.url.externahttps://www.tandfonline.com/doi/full/10.1080/13625187.2017.1317339

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
The use of cyproterone acetate ethinyl estradiol in hyperandrogenic skin symptoms a review.pdf
Tamanho:
667.24 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG